WO1994002507A3 - Methods for detecting pre-clinical iddm - Google Patents

Methods for detecting pre-clinical iddm Download PDF

Info

Publication number
WO1994002507A3
WO1994002507A3 PCT/CA1993/000304 CA9300304W WO9402507A3 WO 1994002507 A3 WO1994002507 A3 WO 1994002507A3 CA 9300304 W CA9300304 W CA 9300304W WO 9402507 A3 WO9402507 A3 WO 9402507A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
iddm
detecting pre
clinical iddm
clinical
Prior art date
Application number
PCT/CA1993/000304
Other languages
French (fr)
Other versions
WO1994002507A2 (en
Inventor
Michael H Dosch
Brian Howard Robinson
Julio Mario Martin
Original Assignee
Hsc Res Dev Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hsc Res Dev Lp filed Critical Hsc Res Dev Lp
Priority to EP93917471A priority Critical patent/EP0652898A1/en
Priority to AU46932/93A priority patent/AU4693293A/en
Priority to JP6504052A priority patent/JPH07509232A/en
Publication of WO1994002507A2 publication Critical patent/WO1994002507A2/en
Publication of WO1994002507A3 publication Critical patent/WO1994002507A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Methods are provided for detecting IDDM and pre-clinical IDDM by obtaining serum samples from a mammal and determining the level of antibodies to bovine serum albumin or a fragment thereof thereof by particle concentration fluoroimmunoassay employing particle-bound bovine serum albumin or fragments thereof as antigen. Novel peptides are provided for use in these methods.
PCT/CA1993/000304 1992-07-28 1993-07-28 Methods for detecting pre-clinical iddm WO1994002507A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP93917471A EP0652898A1 (en) 1992-07-28 1993-07-28 Methods for detecting pre-clinical iddm
AU46932/93A AU4693293A (en) 1992-07-28 1993-07-28 Methods for detecting pre-clinical iddm
JP6504052A JPH07509232A (en) 1992-07-28 1993-07-28 How to detect IDDM before symptoms appear

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2074790 CA2074790A1 (en) 1992-07-28 1992-07-28 Methods for detecting pre-clinical iddm
CA2,074,790 1992-07-28

Publications (2)

Publication Number Publication Date
WO1994002507A2 WO1994002507A2 (en) 1994-02-03
WO1994002507A3 true WO1994002507A3 (en) 1994-03-17

Family

ID=4150211

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1993/000304 WO1994002507A2 (en) 1992-07-28 1993-07-28 Methods for detecting pre-clinical iddm

Country Status (5)

Country Link
EP (1) EP0652898A1 (en)
JP (1) JPH07509232A (en)
AU (1) AU4693293A (en)
CA (1) CA2074790A1 (en)
WO (1) WO1994002507A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029936A1 (en) * 1994-05-03 1995-11-09 Hsc Research And Development Limited Partnership Methods for controlling t lymphocyte mediated immune responses
FR2740223B1 (en) * 1995-10-19 1997-11-14 Commissariat Energie Atomique METHOD FOR DETERMINING AUTO-ANTIBODIES REVEALING PATHOLOGICAL COMPLICATIONS; IN THE BLOOD SERUM, PARTICULARLY DIABETICS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003733A1 (en) * 1990-08-17 1992-03-05 University Of Florida Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003733A1 (en) * 1990-08-17 1992-03-05 University Of Florida Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNALS OF MEDICINE, vol. 24, no. 4, 1991, pages 447 - 452 *
C. MACCRINDLE ET AL.: "Particle Concentration Fluorescence Immunoassay: A New Immunoassay Technique for Quantification of Human Immunoglobulins in Serum", CLINICAL CHEMISTRY, vol. 31, no. 9, September 1985 (1985-09-01), WINSTON US, pages 1487 - 1490 *
CHEMICAL ABSTRACTS, vol. 116, no. 23, 8 June 1992, Columbus, Ohio, US; abstract no. 233099, J.M. MARTIN ET AL.: "Milk Proteins in the etiology of insulin-dependent diabetes mellitus (IDDM)" *
J. KARJALAINEN ET AL.: "A Bovine Albumin Peptide as a Possible Trigger of Insulin-Dependent Diabetes Mellitus", NEW ENGLAND JOURNAL OF MEDICINE, vol. 327, no. 5, 30 July 1992 (1992-07-30), BOSTON, US, pages 302 - 307 *

Also Published As

Publication number Publication date
JPH07509232A (en) 1995-10-12
CA2074790A1 (en) 1994-01-29
WO1994002507A2 (en) 1994-02-03
EP0652898A1 (en) 1995-05-17
AU4693293A (en) 1994-02-14

Similar Documents

Publication Publication Date Title
CA2032907A1 (en) Hepatitis c assay
ZA882998B (en) Simultaneous enzyme immunoassay for detecting antigen and/or antibody in humans
HK1120865A1 (en) Prognostic allergy test
ZA855031B (en) Assay for simultaneous detection of antigen and antibody in given serum
EP1318401A3 (en) Method for the early detection of the seroconversion of an anti hepatitis C virus antibody
TW222686B (en)
KR950008537A (en) Diagnostic Agents for Detection of Antibodies Against Epstein Bacillus (EBV)
FI930106A0 (en) CENP-B epitope
GR3005971T3 (en)
IT8023609A0 (en) COMPOSITIONS SUITABLE FOR SEPARATING RED BLOOD BLOODS FROM SERUM OR PLASMA IN BLOOD SAMPLES FOR ANALYSIS AND THE METHOD THAT USES THEM.
WO1999043703A8 (en) Method for immunochemically assaying anti-hm1.24 antibody
WO1994002507A3 (en) Methods for detecting pre-clinical iddm
AU2353188A (en) A diagnostic agent and a method for the determination of apolipoprotein b
EP0245052A3 (en) Detection of inflammation and novel antibodies therefor
Girault et al. Improving the quality of immunoblots by chromatography of polyclonal antisera on keratin affinity columns
ATE180282T1 (en) ANTIBODIES TEST FOR DETECTING ALCOHOLICS AND MONITORING ALCOHOL INTAKE
CA2120342A1 (en) Epstein-barr virus peptides and antibodies against these peptides
Ishikawa et al. Highly sensitive enzyme immunoassay of rabbit (anti-human IgG) IgG using human IgG—β-D-galactosidase conjugate
WO2001015655A3 (en) Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
AU8630898A (en) Antibodies and other binding molecules specific for hepatitis b viral antigens
Sakakibara et al. Relationship between urinary fibrinogen degradation products and various types of chronic nephritis
AU8008487A (en) A method for determining the presence of substances of diagnostic relevance, in particular antibodies or antigens, by the ELISA method with photometric evaluation
SE9700745D0 (en) Improved immunoassays and improved diagnostic methods and a kit to be used in the methods
IT8906606A0 (en) IMMUNENZYMATIC TEST FOR THE RESEARCH AND DETERMINATION OF BOVINE ANTICASEIN ANTIBODIES IN SERUM
IE882302L (en) Antigen fractions for detecting antibodies indicative of a¹cardiovascular risk

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1993917471

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993917471

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 379489

Date of ref document: 19950710

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1993917471

Country of ref document: EP